Trials / Completed
CompletedNCT00696904
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
Detailed description
Phase 1, double-blind, randomized, placebo-controlled clinical trial in healthy and HCV genotype 1 infected adults to evaluate safety, tolerability, antiviral activity and pharmacokinetics of ABT-333.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-333 | Capsule, see arms for intervention description |
| DRUG | Placebo | Capsule, see arms for intervention description |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-02-01
- First posted
- 2008-06-13
- Last updated
- 2017-11-21
Source: ClinicalTrials.gov record NCT00696904. Inclusion in this directory is not an endorsement.